Eledon pharmaceuticals announces recent business highlights and third quarter 2024 financial results

Completed enrollment of phase 2 bestow trial of tegoprubart in kidney transplantation four months ahead of schedule; on track to report topline results in fourth quarter of 2025 announced positive initial data from first three subjects with type 1 diabetes treated with tegoprubart as part of immunosuppression regimen following islet transplantation in investigator-initiated trial at uchicago medicine announced oversubscribed $85 million underwritten offering, with proceeds expected to extend cash runway to the end of 2026 irvine, calif., nov. 12, 2024 (globe newswire) -- eledon pharmaceuticals, inc. (“eledon”) (nasdaq: eldn) today reported its third quarter 2024 operating and financial results and reviewed recent business highlights.
ELDN Ratings Summary
ELDN Quant Ranking